HPV Vaccine: Why Should Provinces Pay For It?

The HPV vaccine protects against none of the 150 other HPV Strains, is highly expensive, and stops working after just 5 years.
Spread the Word
Listed Under

Chronic Diseases
Hpv Vaccine


Vancouver - British Columbia - Canada

April 17, 2012 - PRLog -- The Center for the Biology of Chronic Disease (CBCD) has recently learned that The Canadian Cancer Advocacy Coalition called on provinces to pay for the HPV vaccine for boys this week. The CBCD cautions that while there may be evidence that the vaccine does help prevent HPV infection with strains 16 and 18, which can cause cervical cancer, and 6 and 11, which can cause genital warts, there are over 150 other types of HPV, which can also cause these diseases, and the HPV vaccine protects against none of these. [1]

Moreover, Merck Pharmaceutical’s own studies show that the efficacy of the vaccine lasts only 5 years. If your 11-year-old son or daughter gets the Gardasil vaccine, it will have stopped working by the time they are 16…right when most teenagers are truly experimenting sexually. [2]

The vaccine is also highly expensive, and costs up to $500 for the required three doses.

Thus, the vaccine provides severely limited protection at an unreasonably high cost for both individuals as well as governments that plan to cover the cost of vaccination, and stops working right when people are at the highest risk for becoming infected with HPV.

According to an article published in Discover Magazine entitled Should Boys Be Given the HPV Vaccine? The Science Is Weaker than the Marketing it was noted: “Giving the shots to boys, they say, promotes gender equity. As a bonus, the vaccine may protect against oral and anal cancers in men who have sex with men.”

Jeanne Lenzer, the author of the article, went on to say, “Merck says that in males, the vaccine is 89 percent effective against genital warts and 75 percent effective against anal cancer. On closer inspection, some of the numbers don’t just deflate, they evaporate.

First off, let’s define the problem: The annual number of deaths from anal-rectal cancer among all men in the U.S. is 300. And how did Merck get its happy statistics on efficacy?

Once again, they reported an idealized benefit by excluding from analysis 1,250 study violators out of 4,055 total test subjects. When the real-world analysis was conducted, the numbers plunged – right down to plum nothing.

After evaluating tissue changes in male genitalia that were suggestive of a cancer precursor, Merck reported that vaccine efficacy against such lesions “was not observed.” [3]

The CBCD questions the wisdom of having Canadian provinces foot the bill to have boys vaccinated against HPV. With the statistical lack of efficacy documented above, the motives for the recommendation by the Canadian Cancer Advocacy Coalition come under suspicion.

However, more concerning than Gardasil’s alleged lack of efficacy is the issue of the presence of HPV DNA fragments in the vaccine.

The CBCD would like to point out that Dr. Hanan Polansky, in his highly acclaimed “Purple” book, explains exactly how certain foreign DNA fragments, at high concentrations, cause major diseases. These diseases include cancer, heart disease, diabetes, autoimmune diseases, and even obesity even when the DNA is broken and not functioning.

In addition, the center encourages biologists, virologists, geneticists and scientists as well as the public to obtain a copy of Dr. Hanan Polansky’s book and read it. The book is available as a free download from the CBCD website.


“I think that this idea (microcompetition) is very interesting and not only gives you a theory about the pathogenesis and pathophysiology of chronic disease, but also a proposal to treatment …” – Harry Elvanides, MD – Research Fellow, Department of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School

Is the Canadian Cancer Advocacy Coalition ignoring the statistical evidence? Have they simply not read the studies referenced in this release? Perhaps they should.

For more information on the Center for the Biology of Chronic Disease, or to schedule an interview with one of our researchers to discuss Microcompetition, please visit http://www.cbcd.net or call 585-250-9999.


[1] Haug CJ, Human Papillomavirus Vaccination – Reasons for Caution, New England Journal of Medicine, August 21, 2008, 359; 861-862.

[2] Tomljenovic L and Shaw CA, Human Papillomavirus (HPV) Vaccine Policy and Evidence-Based Medicine: Are They at Odds? Annals of Medicine December 22, 2011; http://informahealthcare.com/doi/abs/10.3109/07853890.201...

[3] Lenzer J, Should Boys be Given the HPV Vaccine? The Science is Weaker than the Marketing, Discover Magazine, November 14, 2011.

# # #

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

We invite biologists, virologists, and scientists everywhere to download Dr. Polansky’s book here: http://cbcd.net/.
Source:Simon Campbell
Email:***@polydna.com Email Verified
Tags:Canada, Canadian, Cancer, Chronic Diseases, Hpv, Hpv Vaccine, Gardasil, Vaccine
Industry:Health, Government, Medical
Location:Vancouver - British Columbia - Canada
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
polyDNA PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share